Skip to main content

Table 4 Change in total cholesterol, triglyceride, and HDL cholesterol in 72 patients treated with Alirocumab or Evolocumab

From: Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

  Alirocumab 75 mg (n = 25) Follow up length median 24 weeks Alirocumab 150 mg (n = 15) Follow up length median 26 weeks Evolocumab 140 mg (n = 32) Follow up length median 24 weeks
Variable measured   percentile percentile percentile
   25th 50th 75th 25th 50th 75th 25th 50th 75th
Total cholesterol Entry (mg/dl) 172 192 231 227 259 294 222 252 299
Follow up (mg/dl) 118 155 177 114 145 181 117 157 203
Absolute change (mg/dl) −25 −76 −94 −83 −105 −168 −65 −86 −139
 P (paired Wilcoxon) p <.0001 p <.0001 p <.0001
Percent change (%) −14 −32 −45 −34 −48 −53 −26 −39 −52
 P (Wilcoxon) p <.0001 p <.0001 p <.0001
Triglyceride Entry (mg/dl) 96 135 173 124 160 317 101 145 167
Follow up (mg/dl) 80 106 154 76 105 161 80 106 142
Absolute change (mg/dl) +3 −29 −57 −10 −51 −102 +4 −25 −52
 P (paired Wilcoxon) p = .0051 p = .0015 p = .0069
Percent change (%) +3 −21 −33 −12 −32 −41 +4 −23 −35
 P (Wilcoxon) p = .0097 p = .0015 p = .0092
HDL cholesterol Entry (mg/dl) 41 53 61 40 51 57 45 56 68
Follow up (mg/dl) 40 51 65 44 52 65 47 58 75
Absolute change (mg/dl) −1 +2 +5 +1 +7 +10 0 +4 +14
 P (paired Wilcoxon) p = .070 p = .0075 p = .0028
Percent change (%) −2 +5 +11 +3 +11 +17 0 +8 +21
 P (Wilcoxon) p = .092 p = .010 p = .0029